Innovation Pharmaceuticals Inc (IPIX)

[frrol]

Yes and it can be misleading for inexperienced investors. The potential BP partner of course got all the data and doesn't rely on PRs or the clinical trial .org website.

But experienced investors here like you can inform the board about what the data really shows and keep things objective and realistic. You're correct that there are some chicken feathers in our soup, and that the company presents findings in an potentially misleading light. It should be pointed out though that Galera did the same thing with median days. Small biotech can be aggressive with public announcements.

A few things are comforting. While one of the 'feathers' is that the failed arm had an unusually high placebo result, this muted the possible efficacy signal in that arm (since the endpoint was comparative). Of course this raises questions of its own, but the BP is aware of all of this and still agreed to a term sheet. Another issue is our small OM trial sample size, but it is comforting that B demonstrated possible anti inflammatory effect in the P2A IBD trial. In fact the term sheet included OM and IBD. So there's more empirical backing to B's effectiveness than just that small OM trial. The BP is no doubt considering both trials when assessing whether B is potentially effective as an AIF platform.

So we wait to hear something. This is no slam dunk but I think we're still in the game.